Management of MRSA Skin and Soft Tissue Infections

First-Line Oral Options

The American College of Physicians recommends Trimethoprim-sulfamethoxazole (TMP-SMX) as the preferred first-line oral antibiotic for MRSA skin and soft tissue infections, dosed at 1-2 double-strength tablets twice daily for 5-10 days, due to its high clinical effectiveness in MRSA-prevalent settings 1, 2
TMP-SMX has demonstrated high cure rates in observational studies and clinical trials, with excellent in vitro and in vivo activity against community-acquired MRSA 3
The Infectious Diseases Society of America notes that TMP-SMX has limited activity against β-hemolytic streptococci, so it should not be used as monotherapy for nonpurulent cellulitis where streptococcal coverage is needed 1, 3

The American Academy of Pediatrics and the Infectious Diseases Society of America recommend doxycycline 100 mg PO BID or minocycline 200 mg initially, then 100 mg PO BID, as effective alternatives for MRSA skin infections, with high clinical cure rates (83-100%) 1, 3
The Centers for Disease Control and Prevention note that clindamycin 300-450 mg PO TID provides dual coverage for both MRSA and β-hemolytic streptococci, and is particularly useful in pediatric patients (10-13 mg/kg/dose every 6-8 hours) 1, 3
The Society for Healthcare Epidemiology of America warns that clindamycin has a higher risk of Clostridioides difficile infection compared to other oral agents, and should be avoided if local clindamycin resistance rates are high or if inducible resistance (D-test positive) is present 1, 2, 3

The Infectious Diseases Society of America recommends a standard duration of 5-10 days for uncomplicated MRSA skin infections, and extension to 7-14 days for more severe or complicated cases based on clinical response 1, 2
The American College of Physicians advises obtaining cultures from purulent drainage before starting antibiotics to confirm MRSA and guide therapy 1

The Centers for Disease Control and Prevention warn that rifampin should never be used as monotherapy or adjunctive therapy for MRSA skin infections due to rapid resistance development 1, 2, 3
The Society for Healthcare Epidemiology of America notes that beta-lactam antibiotics (penicillins, cephalosporins) are completely ineffective against MRSA and should never be used 2
The Infectious Diseases Society of America advises that incision and drainage is the cornerstone of treatment for abscesses, and antibiotics alone are insufficient 1, 2, 3